Meta-Analysis of 'Sparse' Data : Perspectives from the Avandia Cases
Combining the results of multiple small trials to increase accuracy and statistical power, a technique called meta-analysis has become well established and increasingly important in medical studies, particularly in connection with new drugs. When the data are sparse, as they are in many such cases, certain accepted practices, applied reflexively by researchers, may be misleading because they are biased and for other reasons. We illustrate some of the problems by examining a meta-analysis of the connection between the diabetes drug Avandia (rosiglitazone) and myocardial infarction that was strongly criticized as misleading, but led to thousands of lawsuits being filed against the manufacturer and the FDA acting to restrict access to the drug. Our scrutiny of the Avandia meta-analysis is particularly appropriate because it plays an important role in ongoing litigation, has been sharply criticized, and has been subject to a more searching review in court than meta-analyses of other drugs.
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
S.l.: SSRN ; 2013 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Finkelstein, Michael [VerfasserIn] |
|---|
| Links: |
ssrn.com [kostenfrei] |
|---|
| Anmerkungen: |
In: Jurimetrics, Vol. 52, pp. 123-153, Winter 2012 Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments 2012 erstellt |
|---|
| Umfang: |
1 Online-Ressource (31 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1836101414 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1836101414 | ||
| 003 | DE-627 | ||
| 005 | 20230417235947.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2013 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1836101414 | ||
| 035 | |a (DE-599)KEP084806656 | ||
| 035 | |a (OCoLC)1376292023 | ||
| 035 | |a (ELVSSRN)2073734 | ||
| 035 | |a (EBP)084806656 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a C12 |a K13 |2 jelc | ||
| 100 | 1 | |a Finkelstein, Michael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Meta-Analysis of 'Sparse' Data |b Perspectives from the Avandia Cases |
| 264 | 1 | |a [S.l.] |b SSRN |c 2013 | |
| 300 | |a 1 Online-Ressource (31 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a In: Jurimetrics, Vol. 52, pp. 123-153, Winter 2012 | ||
| 500 | |a Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments 2012 erstellt | ||
| 506 | 0 | |a Open Access |e Controlled Vocabulary for Access Rights |u http://purl.org/coar/access_right/c_abf2 |f unrestricted online access | |
| 520 | |a Combining the results of multiple small trials to increase accuracy and statistical power, a technique called meta-analysis has become well established and increasingly important in medical studies, particularly in connection with new drugs. When the data are sparse, as they are in many such cases, certain accepted practices, applied reflexively by researchers, may be misleading because they are biased and for other reasons. We illustrate some of the problems by examining a meta-analysis of the connection between the diabetes drug Avandia (rosiglitazone) and myocardial infarction that was strongly criticized as misleading, but led to thousands of lawsuits being filed against the manufacturer and the FDA acting to restrict access to the drug. Our scrutiny of the Avandia meta-analysis is particularly appropriate because it plays an important role in ongoing litigation, has been sharply criticized, and has been subject to a more searching review in court than meta-analyses of other drugs | ||
| 700 | 1 | |a Levin, Bruce |e verfasserin |4 aut | |
| 856 | 4 | 0 | |u https://ssrn.com/abstract=2073734 |m X:ELVSSRN |x Verlag |z kostenfrei |
| 912 | |a ZDB-33-ERN | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a ISIL_DE-206 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 951 | |a BO | ||
| 980 | |2 26 |1 01 |x 0206 |b 4306279375 |h OLR-SSRN |y znz |z 08-04-23 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 4302479434 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 05-04-23 | ||
| 981 | |2 26 |1 01 |x 0206 |r https://ssrn.com/abstract=2073734 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://ssrn.com/abstract=2073734 | ||
| 995 | |2 26 |1 01 |x 0206 |a OLR-SSRN | ||